# Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma

> **NCT01169636** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 62 (actual)

## Conditions studied

- Hodgkin's Lymphoma

## Interventions

- **DRUG:** Panobinostat
- **DRUG:** Ifosfamide
- **DRUG:** Mesna
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DRUG:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT01169636
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-31
- **Primary completion:** 2017-05-17
- **Final completion:** 2017-05-17
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2021-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01169636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01169636, "Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01169636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*